• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Feb. 25, 2015

View Archived Issues

On 'Bordeaux' of phase III, Meritage finds Shire buyer: $70M up front for EoE drug

Spun out of Verus Pharmaceuticals Inc. in 2008 to focus on developing oral budesonide suspension (OBS) for eosinophilic esophagitis (EoE) in children and adults, Meritage Pharma Inc. has brought the compound to the brink of phase III and found a buyer in Shire plc, which is paying $70 million up front plus development and regulatory milestone rewards as high as $175 million to acquire the company. Read More

FDA grants approval to Novartis' Farydak for multiple myeloma

Novartis AG salvaged a win, gaining conditional FDA approval for Farydak (panobinostat), the first histone deacetylase inhibitor (HDAC) approved to treat patients with multiple myeloma (MM), despite an advisory committee's concerns that the drug's benefit could outweigh its risks in certain contexts. Read More

With canny Canbex option, Ipsen looks to secure Dysport franchise

Ipsen SA plucked Canbex Therapeutics Ltd. in its prime, gaining an exclusive option to purchase the small University College London (UCL) spin-off and forestall a potential competitor to its Dysport (abobotulinumtoxin A) franchise to treat spasticity across a range of neuromuscular conditions. Read More

Export inhibitors ride SINE wave into neurodegeneration

A class of experimental therapeutics that is being tested in both cancer and wound healing indications may have found another home. Researchers from Karyopharm Therapeutics Inc. and collaborators at the Mount Sinai School of Medicine have reported that treatment with a class of drugs they have termed Selective Inhibitors of Nuclear Export, or SINE compounds, slowed down disease progression in mouse models of multiple sclerosis and axonal damage. Read More

Prexton gets $10M series A funding for mGluR4 program in Parkinson's

DUBLIN – Prexton Therapeutics SA, an early stage CNS drug developer spun out of the Merck Serono arm of Merck KGaA, raised €8.7 million (US$10 million) to move a metabotropic glutamate receptor 4 (mGluR4) agonist development program into clinical trials in Parkinson's disease. Read More

Alkermes beats Street but shares nicked as pain drug halted

Despite fourth quarter and full-year financial results that topped analyst expectations, Alkermes plc saw shares (NASDAQ:ALKS) slide Tuesday after the company halted development of pain candidate ALKS 7106 following disappointing phase I results. Read More

China sees more than 20,000 pharma patents filed in 2013

HONG KONG – China surpassed the U.S. and Japan in 2013 to become the No. 1 patent-filing country in the world with more than 600,000 applications in 2013. A significant chunk of that activity was in the general pharmaceutical space, with more than 20,000 patents filed. Read More

Patent filings up in China: What does that mean for biopharma sector?

SHANGHAI – China has seen a massive rise in patent filings over the last seven years, with the number of published patents growing an average of 16 percent annually. Read More

Regulatory front

With an eye toward greater inclusion, the FDA is seeking comments on specific diseases where significant outcome differences may be anticipated for racial or ethnic subgroups and the differences can be addressed through regulatory science research. Read More

Stock movers

Read More

Financings

Inotek Pharmaceuticals Corp., of Lexington, Mass., said it closed its IPO of 6.7 million shares priced at $6 apiece for aggregate proceeds of $40 million. Read More

Other news to note

Insys Therapeutics Inc., of Phoenix, signed an exclusive sublicense with Gold Coast Therapeutics Inc., of Illinois, to develop a combination of cromolyn sodium and cetirizine (Zyrtec, Johnson & Johnson) as a new chemical entity to treat patients with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). Read More

Pharma: Other news to note

Merck & Co. Inc., of Whitehouse Station, N.J., said it inked an agreement with the Medicines Patent Pool (MPP) to license its pediatric formulations of raltegravir for use in treating HIV-1 infection in infants and children, ages 4 weeks to younger than 12 years, in developing countries. Read More

In the clinic

Biotime Inc., of Alameda, Calif., said the first patient was successfully treated in a pivotal trial in Europe assessing the efficacy of Renevia for the treatment of HIV-associated lipoatrophy, a disorder characterized by abnormal loss of body fat from under the skin that occurs in almost half of the approximately 3 million people on antiretroviral therapy in the U.S. and Europe. Read More

Pharma: In the clinic

Teva Pharmaceutical Industries Ltd., of Jerusalem, said The Lancet Respiratory Medicine has published data from two replicate 52-week phase III global studies on its investigational anti-interleukin-5 (IL-5) monoclonal antibody, reslizumab. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 10, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 10, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 10, 2025
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • Cancer cell in the cross-hairs

    Pan-cancer proteome atlas reveals new biomarkers and targets

    BioWorld Science
    An international group of scientists has completed the first draft of The Pan-Cancer Proteome Atlas (TPCPA). The project is based on mass spectrometry of 22...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe